

Communicable Diseases and Immunization Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: August 3, 2021 Administrative Circular: 2021:31

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization Part 4 – Biological Products & Supporting Documents

Part 4 - Biological Products

Influenza Vaccines

2021/22 Seasonal Influenza Vaccines

- Influenza pages for the 2021/22 season have been revised.
- The eligibility criteria for publicly funded influenza vaccine are unchanged.
- Revisions to the influenza pages include:
 - The vaccine strains contained in the 2021/22 influenza vaccines.
 - The "Intended Use of Influenza Vaccines" table has been revised to include the vaccines for the 2021/22 publicly funded program. The page has a link to the updated Question & Answer Document related to FLUZONE HIGH-DOSE® QUADRIVALENT.
 - New product pages have been added for the 2021/22 influenza season see
 - FLUZONE HIGH-DOSE® QUADRIVALENT vaccine is publicly funded for individuals 65 years of age and older living in long term care, assisted living facilities, and First Nations communities.
 - The dosage of FLUZONE HIGH-DOSE® QUADRIVALENT is 1 dose of 0.7 mL.
 - AFLURIA® TETRA vaccine is not approved for use in those less than 5 years of age.
 - The adverse events content has been revised.

Please remove the following pages:

- 2020/21 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2020
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2020
- Intended Use of Influenza Vaccines: page 1 dated December 2020
- FLUMIST® QUADRIVALENT: pages 1-3 dated December 2020
- FLULAVAL® TETRA: pages 1 & 2 dated December 2020





BC Centre for Disease Control Provincial Health Services Authority

- FLUZONE® QUADRIVALENT: pages 1 & 2 dated December 2020
- INFLUSPLIT® TETRA: pages 1 & 2 dated December 2020
- FLUVIRAL®: pages 1 & 2 dated December 2020
- AGRIFLU®: pages 1 & 2 dated December 2020
- FLUAD®: pages 1 & 2 dated December 2020
- FLUZONE® HIGH-DOSE: pages 1 & 2 dated December 2020

Please add the following pages:

- 2021/22 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2021
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2021
- Intended Use of Influenza Vaccines: page 1 dated August 2021
- FLUMIST® QUADRIVALENT: pages 1-3 dated August 2021
- AFLURIA® TETRA: pages 1 & 2 dated August 2021
- FLULAVAL® TETRA: pages 1 & 2 dated August 2021
- FLUZONE® QUADRIVALENT: pages 1 & 2 dated August 2021
- FLUZONE® HIGH-DOSE QUADRIVALENT: pages 1 & 2 dated August 2021

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated May 2021, and replace with the enclosed updated Title Page and Table of Contents dated August 2021.

Supporting Documents

Latex Content in Vaccines

 AFLURIA® TETRA and FLUZONE® HIGH-DOSE QUADRIVALENT have been added to the list of products that do not contain latex. The following products have been removed from the document as they are not being marketed: AGRIFLU®, FLUVIRAL®, Td POLIO ADSORBED and VAXIGRIP®.

> Please remove page number: 1 dated August 2020 Please add page number: 1 dated August 2021





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM

Medical Director

Communicable Diseases & Immunization Service

BC Centre for Disease Control

With bears

pc:

Provincial Health Officer Dr. Bonnie Henry

Dr. Reka Gustafson Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong Executive Director, Public Health, Planning and Prevention, Population and Public Health Division



